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Abstract
Introduction: Complex psychopathological and behavioral symptoms, such as delusions and
aggression against care providers, are often the primary cause of acute hospital admissions of
elderly patients to emergency units and psychiatric departments. This issue resembles an
interdisciplinary clinically highly relevant diagnostic and therapeutic challenge across many medical
subjects and general practice. At least 50% of the dramatically growing number of patients with
dementia exerts aggressive and agitated symptoms during the course of clinical progression,
particularly at moderate clinical severity.
Methods: Commonly used rating scales for agitation and aggression are reviewed and discussed.
Furthermore, we focus in this article on benefits and limitations of all available data of
anticonvulsants published in this specific indication, such as valproate, carbamazepine,
oxcarbazepine, lamotrigine, gabapentin and topiramate.
Results: To date, most positive and robust data are available for carbamazepine, however,
pharmacokinetic interactions with secondary enzyme induction limit its use. Controlled data of
valproate do not seem to support the use in this population. For oxcarbazepine only one controlled
but negative trial is available. Positive small series and case reports have been reported for
lamotrigine, gabapentin and topiramate.
Conclusion: So far, data of anticonvulsants in demented patients with behavioral disturbances are
not convincing. Controlled clinical trials using specific, valid and psychometrically sound
instruments of newer anticonvulsants with a better tolerability profile are mandatory to verify
whether they can contribute as treatment option in this indication.
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A common problem in elderly demented patients is
aggressive behavior against nurses or care providers. This
is particularly true with a dramatically increasing preva-
lence and clinical relevance during moderate to severe
clinical stages of the disease. Studies conducted in nursing
facilities showed that 2/3 of their population suffers from
a dementia syndrome and almost all of them demonstrate
psychopathological and behavioral symptoms [1-3]. The
most common symptoms – normally clinically associated
with underlying moderate to severe Alzheimer's disease
(AD) – are aggression, irritability and agitation. Half of a
sample of outpatients with AD is suggested to present
with agitation, 1/3 with violent behavior and 1/4 with ver-
bal outbursts [4].
There still exists a considerable confusion in the psychiat-
ric community as to how aggression and agitation are to
be specifically defined and best distinguished [5]. The
core features of agitation generally described include rest-
lessness with excessive or semipurposeful motor activity,
irritability, heightened responsiveness to internal and
external stimuli, and an unstable course [6]. Aggression
can be distinguished in a verbal, physical and sexual sub-
type and is not considered as core feature of agitation.
However, features disposing to aggression and the transi-
tion from simple agitation to aggression are still poorly
understood.
With respect to the etiology of aggression in demented
patients Raskind (1999) describes the interaction of three
factors, which lead to aggression in this population [5]:
The basis is presumably a neurobiological dysregulation,
e.g. an hyperdopaminergic state or noradrenergic and γ-
aminobutyric acid disturbances in the substantia nigra
that may lower the threshold for the expression of aggres-
sion. Cognitive impairment in demented patients
increases also the aggressive potential due to mispercep-
tions, poor insight or desinhibition. Finally, factors like
an unfamiliar environment might lead to an exacerbation
of aggressive symptoms. In this respect, climate, noise
level and general level of stimulation has to be balanced.
If possible at all, changes of these conditions are often not
satisfying, even in combination with behavioral therapy
or strategies of verbal de-escalation. Therefore, pharmaco-
therapy plays a significant role in diminishing symptoms,
stabilizing mood and consecutively enhancing quality of
life for patients, as much as family members and care pro-
viders.
Measures
Aggressive behavior belongs to the complex of so-called
non-cognitive symptoms of dementia. These include a
variety of psychopathological and behavioral categories
including delusions, hallucinations, depression, anxiety,
apathy, irritability, euphoria, desinhibition as well as
aggression, agitation and disruptive behavior. To classify
these neuropsychiatric disturbances the term Behavioral
and psychological symptoms of Dementia (BPSD) was
coined. The complexity and importance of behavioral and
psychopathological phenomena in dementia requires that
they can be differentially assessed in the course of the dis-
ease and quantified for research purposes [7]. This holds
particularly true for the measurement of therapeutic
response in drug efficacy studies. However, the lack of
clear definition and boundaries between entities creates
automatically problems of measurement.
A number of scales have been devised for the assessment
of BPSD, but up to now no single scale is considered
clearly superior to the others [8]. Nonetheless, there are
several significant differences between the available
instruments with respect to their validity and psychomet-
ric properties. Furthermore, some of these scales are rather
unspecific with regard to age and diagnosis, like the Overt
Aggression Scale [9], the Overt Agitation Scale [10], and
the Brief Agitation Rating Scale (BARS) [11]. Many of the
recent studies analysed in this review also apply subitems
of the Brief Psychiatric Rating Scale (BPRS/e.g. subfactor
hostility or agitation) or very global instruments such as
the Clinical Global Impression of Change (CGIC) or even
Young-Mania Rating Scale (YMRS) to define treatment
response. However, these instruments were not primarily
developed for geriatric patients with dementia.
A scale that measures global aspects of BPSD in dementia
is the Behavioral Pathology in Alzheimer's Disease Rating
Scale (BEHAVE-AD), a 25-item rating scale with assess-
ments on a 4-point severity score [12]. More specific with
respect to aggressive and disruptive behavior is the Behav-
ioral and Emotional Activities manifested in Dementia
Scale to score troublesome and disruptive behavior with
items that have a strong correlation with standard scales
like the BPRS and the Sandoz Clinical Assessment-Geriat-
ric [13]. The Troublesome Behavior Scale defines 14 items
-in combination with their frequency of occurrence- to
describe disruptive or burdensome behavior of the elderly
demented patient [14]. Other useful and practicable rat-
ing scales are the Cohen Mansfield Agitation Inventory
(CMAI), which gives a detailed assessment of agitation
[15] and the Disruptive Behavior Rating Scale [16]. The
latter includes a set of rating scales used to measure four
different dimension of disruptive behavior that present
frequent problems in patients with dementia, such as
physical and verbal aggression, agitation, and wandering.
However, only few experiences exist for the use of the
CMAI and the Disruptive Behavior Rating Scale as end-
points in clinical drug trials.Page 2 of 8
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clinical trial settings is the Neuropsychiatric Inventory
(NPI) by Cummings [7,17]. The NPI assesses 12 different
subtypes of behavioral disturbances concerning the psy-
chopathology in dementia, including delusions, halluci-
nations, dysphoria, anxiety, agitation, euphoria, apathy,
irritability, aberrant motor behavior, night-time behavior
disturbances and change in appetite and eating behavior.
It is based on observations made by family or professional
caregivers. A screening question is asked first, followed by
subquestions if the response to the screening question
suggests the presence of abnormalities involving that neu-
ropsychiatric domain. After administration of the sub-
questions, the caregiver rates the frequency and severity of
each abnormality as well as the caregivers distress associ-
ated with each neuropsychiatric alteration. Having two
different scores for severity and frequency for each
domain potentially increases the utility of the NPI in drug
efficacy studies because effects on frequency (events occur
less frequently but each event has not changed severity)
versus effects on severity (events occur just as often after
treatment but are of diminished intensity) can be sepa-
rated. Previous studies suggest that the NPI is psychomet-
rically sound, comprehensive and sensitive to change
[17]. Accordingly, it has been successfully used in drug tri-
als to score changes in disruptive behavior and other neu-
ropsychiatric symptoms after treatment [18-21].
Many of the more recent studies analysed in the present
review do not use specific scales for the assessment of
BPSD but rather apply instruments which were originally
developed for general adult psychiatric populations (e.g.
BPRS or the CGIC). This relates to the fact that many of
the more detailed and specific instruments for the valid
assessment of BPSD became only available during the last
decade. This does not necessarily imply that the results are
less meaningful but should be taken in mind as a poten-
tial limitation when interpreting the conclusions of those
older studies.
Anticonvulsants
Anticonvulsants, such as carbamazepine (CBZ), valproate
(VPA) and lamotrigine (LTG) have become established
treatment options in bipolar disorder. In this article we
will update their potential effectiveness as antiaggressive
drugs in elderly demented patients, looking also into
newer drugs of this class like oxcarbazepine (OXC),
topiramate (TOP) and gabapentin (GPN).
Carbamazepine
CBZ shows a blockade of voltage-dependent sodium, and,
additionally, calcium L- type channels. Furthermore, CBZ
reinforces repolarization by potassium outflow, and has
GABAergic, adenosinergic and glutamate antagonistic
properties. In the kindling model that serves as a lab
bench model for the progression of epilepsies and recur-
rent affective disorders, CBZ shows reasonable antikin-
dling properties [22]. CBZ's efficacy in behavioral
syndromes might be related to its inhibitory effects on
limbic system kindling, increased locus coeruleus firing
and enhanced tryptophan levels [23].
First reports of CBZ in the treatment of emotionally dis-
turbed patients are reaching back to the 70 s [24,25]. In
the following decade some single case reports of CBZ fol-
lowed showing improvements in behavioral disturbances
in demented patients [26-28].
CBZ was also administered in an open trial to eight
patients with organic brain disease characterized by
aggressive and assaultive behavior refractory to conven-
tional treatment [29]. Improvement was observed in all
patients, with the average number of assaults over pre-
treatment and post-treatment observation periods declin-
ing by more than half. Nine outpatients who met well-
defined criteria for probable AD and who had significant
behavioral agitation failed to improve with antipsychotic
therapy and were subsequently treated with CBZ in
another open study [30]. Five patients showed a clear
improvement, and one patient an equivocal response
according to clinical evaluation and BPRS scores.
A further open prospective study investigated the effects of
CBZ on agitation, hostility, and uncooperativeness in 15
severely demented Alzheimer's inpatients who had failed
to respond to prior treatment with antipsychotics [31].
Severity of psychopathologic symptoms was again
assessed by the BPRS with a significant improvement in
activation and hostility after 4 weeks.
A negative small placebo-controlled, double-blind study
of CBZ in 19 elderly demented patients was reported in
1982 [32]. In dosages of 100–300 mg/d for a period of 4
weeks no response was noted in wandering, aggression or
agitation and a worsening of cognitive functioning was
even observed using the Behavior Rating Scale and the
Clifton Assessment Scedule (CAS). Low doses (average
serum levels 3.5 microg/ml) of CBZ might be a possible
reason for these negative results.
More promising results evolved in two further controlled
studies by Tarot and colleagues [33,34]. The first was a
nonrandomized, placebo-controlled, crossover trial with
25 patients with dementia and verbal or physical aggres-
sion [33]. Median total BPRS score decreased 7 points on
CBZ versus 3 on placebo. Sixteen subjects were rated as
improved globally on CBZ versus four on placebo. CBZ
was titrated to serum levels between 5 and 8 microg/ml
with good tolerability. The following 6-week, rand-
omized, multisite, parallel-group study, screened 163Page 3 of 8
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patients who received up to 300 mg CBZ or placebo for 6
weeks [34]. CBZ was started with 100 mg/d and increased
-according to the protocol- by 50 mg every 2–4 days. If no
toxic side effect occurred, a serum level of 5–8 microg/ml
was maintained. CGIC, BPRS, Overt Aggression Scale and
Behavior Rating scale of dementia were applied. Over 6
weeks the mean total BPRS score decreased 7.7 points for
the CBZ group and 0.9 for the placebo group, and the
weekly scores indicated a gradual divergence between the
two groups. CGI ratings showed global improvement in
77% of the patients taking CBZ and 21% of those taking
placebo. Side effects did not occur significantly more
often in the CBZ group compared to placebo group.
Therefore, serum levels of 5–8 microg/ml were recom-
mended by the investigators. One patient was withdrawn
from the study because of tics and extensive sedation
occurring at a dose of 200 mg/d. One patient developed
ataxia, but remained in the study. No deterioration of cog-
nitive function was observed.
Another 6-week, randomized, double-blind, placebo-con-
trolled, parallel-group trial investigated 400 mg CBZ in 21
agitated subjects (16 completers) who had been treated
unsuccessfully with antipsychotics. A greater improve-
ment in the CBZ group than in the placebo group on the
CGI and especially on the hostility item of the BPRS was
observed [35].
In conclusion, CBZ seems to be an effective treatment in a
reasonable number of severely demented and agitated
patients. However, the efficacy and safety of long-term use
remain to be established and use is often limited by phar-
macokinetic drug interactions secondary to its enzyme-
inducing effect.
Oxcarbazepine
Oxcarbazepine (OXC) is the keto-derivative of CBZ and
represents an alternative to CBZ due to its suggested better
tolerability profile. In a randomized, placebo-controlled,
double-blind trial in patients with bipolar disorder a sig-
nificant effect of this drug in the prevention of impulsivity
and related behaviors was observed [36], suggesting that
it might also play a role for the treatment of impulsivity in
patients with dementia. So far, only one clinical study in
this population has yet been published to investigate this
hypothesis. To evaluate the efficacy of OXC in the treat-
ment of agitation and aggression in patients with AD, vas-
cular dementia or both a pharmaceutical industry
independent 8-week, multicenter, randomized, double-
blind, placebo-controlled trial was published recently
[19]. Changes in the agitation and aggression subscore of
the NPI were the primary outcomes. The secondary out-
comes were the changes in the caregivers' total burden
scores (measured by the NPI) and changes in the Brief Agi-
tation Rating Scale. In total, 103 institutionalized patients
at 35 sites were randomized to the trial. After 8 weeks, no
statistically significant differences were found between the
2 groups for all outcomes. A trend was observed in favour
of the OXC group in the reduction in the scores on the
BARS.
Due to this negative controlled study, at present the use of
OXC in this indication can not be recommended. Results,
however, have to be replicated but its use in dementia
might be limited as OXC causes more often hyponatremia
than CBZ, especially in older patients [37,38].
Valproate
VPA blocks voltage-dependent sodium channels and cal-
cium T- type channels and reinforces repolarisation by
shifting the inactivation curve of early potassium outward
currents towards more positive membrane potentials. Fur-
thermore, it has indirect GABAergic and serotonergic
properties. On the intracellular level, it interferes with the
inositol phosphate metabolism and activates antioxidant
cell survival proteins, e.g. bcl-2 or Rho-Kinases [39]. In the
kindling model VPA has pronounced antikindling proper-
ties [22].
VPA has a variety of indications. Besides epilepsy and
acute mania, it seems to be effective in panic disorder,
alcohol and sedative withdrawal, agitation as well as
behavioral dyscontrol [40,41]. In an open trial 10 patients
diagnosed with personality disorder with impulsive
aggressive behavior were treated with VPA [42]. In six of 8
completers irritability and impulsive aggressive behavior
improved significantly.
One of the first open trials with VPA in the treatment of
severe behavioral disturbances in dementia was con-
ducted in 4 patients receiving VPA for 1 to 3 months [43].
Two patients showed significant improvement in behav-
ior, a third had a transient response. Another open trial in
elderly demented and agitated patients was conducted in
1995 [44]. A global rating scale was used by the nursing
staff biweekly to assess improvement which was a 50% or
greater reduction in the frequency of episodes of behavio-
ral agitation in 8 of 10 patients. The dosage was 375–750
mg/d and was well tolerated and safe. Similar positive
results were documented by Haas and colleagues (1997)
in a trial with 12 cognitively impaired and aggressive eld-
erly patients and by Porsteinsson and colleagues (1997)
who reported on 13 patients suffering from agitation and
neuropsychiatric disorders [45,46]. Drug response was
rated on the CGIC.
VPA alone or in combination with antipsychotics was
compared in an open study with 25 patients suffering
from dementia with behavioral disturbances [47]. UsingPage 4 of 8
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responded with 7 out of 15 patients (47%) when given
VPA in monotherapy and with 7 out of 10 (70%) when
added to antipsychotic treatment. The mean daily dose
was 1650 mg/d with a mean blood level of 64 microg/ml.
Except for reversible sedation in 8 patients and transient
worsening of gait and confusion in 1 subject, no other
side effects were observed. In an open-label extension trial
of a double-blind study ongoing treatment with VPA
(mean: 851 mg/d) was associated with improvement in
measures of agitation in 46 patients [48]. Behavior was
rated on the Social Dysfunction and Aggression Scale 9
(SDAS-9), a Dutch version of the Behavioral Observation
Scales for Intrmural Psychogeriatrics (GIP), and the CGIC.
Sixty percent of subjects had no side effects and 33% had
side effects that were rated as mild.
The goal of a study by Forester and colleagues (2007) was
to determine if manifestations of agitation, such as physi-
cal aggression, physically nonaggressive or verbally agi-
tated behavior, show different degrees of response to VPA
alone or in combination with second-generation antipsy-
chotic agents [20]. In a 6-week, open-label, naturalistic
pilot study of patients aged > 60 years recruited from a ger-
iatric psychiatry inpatient unit, 2 nursing homes, and 4
assisted living residences the primary outcome measure
was measured on the CMAI and the NPI -Nursing Home
version (NPI-NH). Fifteen patients were included in the
study. Patients with higher levels of agitation receiving
VPA had reduced agitation on the physical aggression sub-
scale of the CMAI. VPA was less effective on physically
nonaggressive behavior and verbal agitation. Irritability,
as measured on the NPI-NH, was also reduced. Patients
who received both VPA and an antipsychotic agent were
responsive at lower doses of VPA. In either case, the effec-
tive dosage of VPA was lower than that commonly used
for epilepsy or mania in elderly patients. The most com-
mon adverse events included somnolence and gait distur-
bance.
The positive results of open-trials are somewhat in contra-
diction with results of controlled trials of VPA in
demented patients with behavioral disturbances.
In 2002 a randomized, placebo-controlled, double-blind
cross-over study was published with 42 demented and
aggressive patients treated with a fixed dose of 480 mg/d
of VPA (plasma levels of VPA: 40,9 +/- 10,8 microg/ml)
[49]. Primary outcomes were again the SDAS-9 and the
CGIC. The treatment with VPA showed no difference
compared to placebo on aggressive behavior but signifi-
cant improvement on restless, melancholic and anxious
behavior. Possible limitations of this study were the low
dose of VPA and the relatively short treatment period. 39
patients were further examined in a twelve-week open
label follow-up study [50]. Maintaining the same dosage
of VPA aggressive, non-social, apathetic, disorientated
behavior and distorted memory improved at week 12
compared to week 0. The authors used apart from the
SDAS-9 the Behavior Observation scale for Intramural
Psychogeriatrics and the CGI.
A large placebo-controlled study included 153 nursing
home residents with probable or possible AD complicated
by agitation [51]. Patients receiving a mean dose of 800
mg/d VPA over a period of 6 weeks did not differ from
patients treated with placebo. The primary outcome meas-
ure was change from baseline on the BPRS Agitation fac-
tor. Secondary outcomes included total BPRS, CGIC,
CMAI score, and measures of safety and tolerability. In
summary, this study did not support the use of VPA in
demented elderly and agitated patients.
Another very small randomized, double-blind trial was
conducted with 14 patients with AD and agitation [21].
Patients were assessed with the NPI and CMAI at baseline
and after 6 weeks of treatment with VPA and placebo, with
2 weeks between phases to allow for placebo washout and
tapering. The results were also negative and agitation and
aggression scores even worsened during VPA treatment
when compared to placebo.
In conclusion, it seems that VPA currently can not be rec-
ommended in demented and aggressive elderly patients,
even though open trials and extension studies of control-
led trials are positive and some of the controlled studies -
as stated before- show some limitations, such as small
numbers of patients included or low doses of VPA. A
Cochrane review published in 2004 concluded that VPA
in low doses is ineffective to control agitation/aggression
in demented patients and that higher doses of VPA are
associated with unacceptable side effects [52].
Lamotrigine
Lamotrigine (LTG) became a main focus of interest
beyond its primary indication, epilepsies, as it is sharing
many cellular mechanisms of action with the established
mood stabilizers CBZ and VPA. It mainly reinforces the
repolarisation by enhancing an early potassium outward
current [53], blocks voltage-dependent sodium and cal-
cium channels and reduces glutamate release. Intracellu-
lar actions comparable to VPA may be assumed, but have
not been elucidated so far. In the kindling model LTG has
similar pronounced antikindling properties as VPA [22].
Furthermore, LTG appears to have neuroprotective effects
but its potential to induce severe cutaneous side effects
has to be taken into account.
One case report and one case series indicate that LTG
might be a successful strategy in patients with dementiaPage 5 of 8
(page number not for citation purposes)
Clinical Practice and Epidemiology in Mental Health 2009, 5:14 http://www.cpementalhealth.com/content/5/1/14and aggressive behavior or agitation [54,55]. The first
publication reports on a dramatic improvement with the
introduction of LTG (100 mg/d) in a patient with frontal
lobe dementia and a large history of verbal and physical
aggressions [54]. A retrospective medical record review of
the effectiveness of LTG for manic-like symptoms and agi-
tation in 5 demented patients was conducted in the sec-
ond [55]. In dosages of LTG between 100 and 300 mg/d
patients showed a decrease in the Young-Mania Rating
Scale through 5 months. Obvious limitations of this case
series are the small number of patients and the use of a
scale, which is normally applied in bipolar disorder.
To define the role of LTG in this indication, larger and
controlled trials are warranted.
Gabapentin
Gabapentin, with indirect GABAergic properties, may act
mainly via blockade of L type calcium channels and pos-
sibly sodium channels as well; however, its decisive mech-
anisms of action both in epilepsy and pain treatment are
still unclear.
In a case report of a patient suffering from vascular
dementia and aggressive behavior the addition of gabap-
entin resulted in reduced agitation, sexual inappropriate-
ness, and lability [56]. The dosage of 900 mg/d was well
tolerated. An open 15-month investigation of gabapentin
included 20 demented patients with behavioral altera-
tions [57]. The results of this study in patients with prob-
able AD with behavioral alterations and serious
comorbidities indicate that gabapentin provides signifi-
cant and sustained efficacy in terms of behavior, with
associated reductions in caregiver burden. No patient
withdrew during the study and no side effects or drug
interaction occurred. A recent review of gabapentin in this
indication suggests benefits but a limited support for the
off-label use of gabapentin for the treatment of BPSD due
to the dearth of available data [58].
In conclusion, gabapentin in aggressive demented
patients seems to be worthwhile to be investigated fur-
ther, also due to its good tolerability profile, but control-
led studies are mandatory to verify its role in BPSD.
Topiramate
Topiramate (TOP) is a structurally unique antiepileptic
drug in so far as it belongs to a sulfamate-substituted d-
fructose substance group. However, many of the known
mechanisms of action of TOP are similar to those of estab-
lished AEDs, especially the putative mood stabilizers CBZ,
VPA and LTG. TOP modulates sodium conductance,
inhibits L-type calcium channels at low serum concentra-
tions, potentiates GABAergic inhibition, decreases AMPA/
kainate receptor-mediated currents and is a weak inhibi-
tor of carbonic anhydrase [59].
TOP has a good tolerability profile but a possible cogni-
tive impairment has to be taken into account when
applied to demented patients [60].
Fhager and colleagues (2003) retrospectively evaluated
the outcome of TOP used on 15 demented patients who
were severely aggressive and failed to respond to antipsy-
chotics [61]. Patients received between 25 mg to 150 mg
TOP daily either in monotherapy or additional to an
antipsychotic. Symptoms were rated using Cohen Mans-
field Agitation Inventory at baseline and 2 weeks of receiv-
ing TOP. Both groups showed significant improvement in
aggressive behavior and no side effects were reported.
Despite of these positive results its use in demented
patients has to be considered with caution, because of its
lack of controlled data. Furthermore, a possible deleteri-
ous effect on cognitive functions in this fragile population
has to be considered.
Conclusion
With an increased life expectancy the global population
will age and suffer more frequently from dementia and
associated non-cognitive problems, such as aggressive or
agitated behavior. A recent prevalence study of BPSD in
dementia confirmed again that nearly all 587 demented
subjects suffered from behavioral and psychological
symptoms [62]. Assessment and treatment of dementia
therefore is crucial and important to reduce stress in
affected patients and their families. An individual treat-
ment plan with cognitive behavioral therapeutic
approaches and verbal de-escalation might be the best
option to cope with demented elderly and aggressive
patients. Its application, however, remains often unrealis-
tic due to a lack of financial resources to enhance educa-
tion and the presence of nurses or care providers in
nursing homes. Therefore, pharmaceutical interventions
will often remain necessary. Unfortunately, emerging evi-
dence indicates that some treatment options, such as typ-
ical and atypical antipsychotics, have limitations in this
population due to possible side effects, such as extrapy-
ramidal, cardiovascular or metabolic side effects.
Anticonvulsants are an interesting class for the potential
use in this population as they are successfully prescribed
in similar behavioral disturbances and in bipolar disor-
der. Three reviews on the use of anticonvulsants in behav-
ioral alterations in demented patients were published in
the last three years [63-65]. Whereas Guay (2007) was
more supportive on the use of anticonvulsants in this
indication [63], the other two authors were rather critical
and pronounced the lack of controlled data [64,65]. In
our opinion, the data of anticonvulsants in dementedPage 6 of 8
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patients clearly benefit from the use of anticonvulsants.
Most data are available for CBZ and VPA so far. CBZ seems
to be the most effective drug, but pharmacokinetic inter-
actions and side effects are likely to occur, particularly in
this vulnerable population which is often treated with
polypharmacy. VPA is better tolerated but controlled data
are not conclusive for the use in this indication. The liter-
ature regarding newer anticonvulsants, such as OXC, LTG,
gabapentin or TOP, is modest in volume. With one nega-
tive controlled study OXC can not be recommended so
far, but certainly more studies are warranted to possibly
replicate findings. Controlled trials in future with LTG,
gabapentin or TOP will help us to understand its effective-
ness and safety in demented patients with behavioral
alterations. However, possible side effects, such as
hyponatremia with OXC or cognitive impairment with
TOP have to be taken into account when new studies are
planned.
One limitation of a majority of the published studies is
the use of rather global and non-specific instruments for
the measurement of drug response. This applies particu-
larly for the more recent studies. In the meantime several
more specific, valid and psychometrically sound instru-
ments for the assessment of behavioral disturbances in
dementia (e.g. the NPI) are available and evaluated with
respect their usefulness and validity. These should be
applied in future studies.
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